Assembly Biosciences Price to Book Ratio 2010-2023 | ASMB
Historical price to book ratio values for Assembly Biosciences (ASMB) over the last 10 years. The current price to book ratio for Assembly Biosciences as of April 26, 2024 is 1.78.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Assembly Biosciences Price/Book Ratio Historical Data |
| Date |
Stock Price |
Book Value per Share |
Price to Book Ratio |
| 2024-04-26 |
12.65 |
|
1.69 |
| 2023-12-31 |
9.84 |
$7.50 |
1.31 |
| 2023-09-30 |
10.62 |
$9.52 |
1.12 |
| 2023-06-30 |
13.80 |
$12.58 |
1.10 |
| 2023-03-31 |
10.08 |
$16.23 |
0.62 |
| 2022-12-31 |
15.60 |
$20.29 |
0.77 |
| 2022-09-30 |
19.68 |
$25.36 |
0.78 |
| 2022-06-30 |
25.20 |
$30.77 |
0.82 |
| 2022-03-31 |
24.72 |
$36.61 |
0.68 |
| 2021-12-31 |
27.96 |
$42.14 |
0.66 |
| 2021-09-30 |
41.76 |
$57.29 |
0.73 |
| 2021-06-30 |
46.56 |
$63.56 |
0.73 |
| 2021-03-31 |
55.20 |
$74.01 |
0.75 |
| 2020-12-31 |
72.60 |
$84.88 |
0.86 |
| 2020-09-30 |
197.28 |
$98.65 |
2.00 |
| 2020-06-30 |
279.84 |
$97.74 |
2.86 |
| 2020-03-31 |
177.96 |
$92.64 |
1.92 |
| 2019-12-31 |
245.52 |
$100.74 |
2.44 |
| 2019-09-30 |
117.96 |
$72.61 |
1.62 |
| 2019-06-30 |
161.88 |
$81.78 |
1.98 |
| 2019-03-31 |
236.28 |
$89.46 |
2.64 |
| 2018-12-31 |
271.44 |
$99.19 |
2.74 |
| 2018-09-30 |
445.68 |
$108.18 |
4.12 |
| 2018-06-30 |
470.52 |
$51.89 |
9.07 |
| 2018-03-31 |
589.68 |
$60.29 |
9.78 |
| 2017-12-31 |
543.00 |
$67.43 |
8.05 |
| 2017-09-30 |
419.04 |
$32.54 |
12.88 |
| 2017-06-30 |
247.80 |
$39.09 |
6.34 |
| 2017-03-31 |
305.88 |
$47.06 |
6.50 |
| 2016-12-31 |
145.80 |
$55.60 |
2.62 |
| 2016-09-30 |
86.52 |
$62.75 |
1.38 |
| 2016-06-30 |
66.60 |
$70.08 |
0.95 |
| 2016-03-31 |
60.24 |
$76.16 |
0.79 |
| 2015-12-31 |
90.12 |
$82.75 |
1.09 |
| 2015-09-30 |
114.72 |
$87.39 |
1.31 |
| 2015-06-30 |
231.12 |
$91.39 |
2.53 |
| 2015-03-31 |
158.88 |
$92.06 |
1.73 |
| 2014-12-31 |
94.32 |
$65.89 |
1.43 |
| 2014-09-30 |
98.28 |
$65.22 |
1.51 |
| 2014-06-30 |
78.60 |
$52.05 |
1.51 |
| 2014-03-31 |
76.50 |
$57.58 |
1.33 |
| 2013-12-31 |
229.20 |
$70.91 |
3.23 |
| 2013-09-30 |
173.40 |
$87.29 |
1.99 |
| 2013-06-30 |
144.00 |
$95.20 |
1.51 |
| 2013-03-31 |
179.40 |
$107.55 |
1.67 |
| 2012-12-31 |
129.60 |
$82.65 |
1.57 |
| 2012-09-30 |
214.80 |
$97.45 |
2.20 |
| 2012-06-30 |
256.20 |
$118.99 |
2.15 |
| 2012-03-31 |
598.20 |
$132.82 |
4.50 |
| 2011-12-31 |
480.48 |
$167.08 |
2.88 |
| 2011-09-30 |
541.80 |
$252.62 |
2.14 |
| 2011-06-30 |
885.60 |
$78.33 |
11.31 |
| 2011-03-31 |
711.00 |
$104.62 |
6.80 |
| 2010-12-31 |
397.20 |
$103.45 |
3.84 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.073B |
$0.007B |
|
Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York.
|
